Volume 14, Number 4—April 2008
CME ACTIVITY - Research
β-Herpesviruses in Febrile Children with Cancer
Table 2
Characteristic | Cancer patients, no. positive/no. tested (%) |
Transplant patients (n = 9), no. positive/no. tested (%) | |
---|---|---|---|
Leukemia (n = 9) | Solid tumor (n = 20) | ||
CMV PCR | |||
Whole blood | 1/6 (17) | 0/5 | 3/7 (43) |
PBMC | 1/7 (14) | 0/16 | 2/8 (25) |
Plasma | 0/9 | 0/20 | 2/9 (22) |
All tests |
1/9 (11) |
0/20 (0) |
3/9 (33) |
HHV-6 PCR | |||
Whole blood | 2/6 (33) | 0/5 | 2/7 (29) |
PBMC | 1/7 (14) | 1/16 (6) | 3/8 (38) |
Plasma | 0/9 | 0/19 | 1/9 (11) |
Lymphocyte culture | 1/8 (13) | 0/16 | 0/9 |
All tests |
3/9 (33) |
1/20 (5) |
3/9 (33) |
HHV-7 PCR | |||
Whole blood | 0/6 | 0/5 | 0/7 |
PBMC | 0/7 | 0/16 | 0/8 |
Plasma | 0/9 | 0/20 | 0/9 |
All tests | 0/9 | 0/20 | 0/9 |
*Data are not shown for study participant 23, a patient with lymphoma who did not have β-herpesviruses detected in whole blood, PBMC, or plasma. CMV, cytomegalovirus; PBMC, peripheral blood mononuclear cells; HHV-6, human herpesvirus 6.
1Current affiliation: University of North Carolina, Chapel Hill, North Carolina, USA
2Current affiliation: Wayne State University School of Medicine, Detroit, Michigan, USA
Page created: July 15, 2010
Page updated: July 15, 2010
Page reviewed: July 15, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.